| Old Articles: <Older 4621-4630 Newer> |
|---|
 |
The Motley Fool
February 29, 2008
Brian Lawler |
Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year.   |
The Motley Fool
February 29, 2008
Brian Lawler |
Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs. |
The Motley Fool
February 29, 2008
Brian Lawler |
NeurogesX Gets a Painful Kick in the Pants NeurogesX's lead drug fails in clinical testing. |
The Motley Fool
February 29, 2008
Brian Orelli |
Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
February 29, 2008
Brian Orelli |
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. |
InternetNews
February 28, 2008 |
Google Eyes Medical Records, Data Sharing Business Google has unveiled a plan to help U.S. patients gain control of their medical records and is working with doctors' groups, pharmacies and labs to help them securely share sensitive health data. |
The Motley Fool
February 28, 2008
Brian Lawler |
Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note. |
The Motley Fool
February 28, 2008
Brian Lawler |
ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline. |
The Motley Fool
February 28, 2008
Brian Lawler |
A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri. |
| <Older 4621-4630 Newer> Return to current articles. |
